HoneyNaps

HoneyNaps develops AI-based sleep disorder diagnosis and bio-signal monitoring systems, offering a comprehensive platform called SOMNUM for real-time sleep bio-signal monitoring, bio-signal management and analysis, and AI-driven disease diagnosis software. The company's technology has received FDA certification for its AI sleep data diagnosis algorithm, enabling medical professionals to assess sleep disorders with clinical-grade accuracy. HoneyNaps focuses on the 4P medicine approach: Prevention, Prediction, Participation, and Personalization, developing technologies for disease prediction and bio-signal monitoring throughout a patient's lifetime. The platform provides therapeutic care for sleep disorders and aims to make medical treatment more accessible through shared platform technology. The company maintains offices in Seoul, South Korea and Cambridge, Massachusetts, with R&D partnerships at Yonsei University. Founded in 2015 and headquartered in Seoul, South Korea, HoneyNaps has raised $15.5M in Series B funding from investors including Industrial Bank of Korea, Hi Investment, and QUAD.